Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule

Kelowna, BC – October 21, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 (GLP-1-H26-7) which is evaluating two oral DehydraTECH-semaglutide (“DHT-sema”) compositions against Novo’s® commercially available Wegovy® tablets, over a 5-week duration (the “ Study ”). The final Study arm was fully enrolled and began dosing, as scheduled, in early October. This final group is expected to complete their dosing in mid-November, to be followed by completion of all laboratory sample analyses and reporting. Lexaria will provide a further progress update once all dosing has been completed. About the Study The Study is investigating three separate arms to assess safety & tolerability as well as PK properties that will compare SNAC-inclusive, DHT-sema compositions formulated in both tablet and capsule formats to commercially available Wegovy® tablets. The Study is being conducted under fasted pre-dose conditions similar to the advised administration criteria of Novo’s oral semaglutide products. The 5-week

Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes